Exicure (FRA:2H0) Long-Term Debt: €0.00 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:2H0 Exicure Inc FRA:2H0
30 GF Score
Price €1.16
GF Value €0.36
! 2 Warning Signs
View Full Analysis

What is Exicure Long-Term Debt?

Exicure FRA:2H0 +0.87% 30 Long-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus rates FRA:2H0 with a GF Score™ of 30/100 and a GF Value™ of €0.36. The stock has 2 warning signs investors should review.

Exicure's Long-Term Debt for the quarter that ended in Mar. 2026 was €0.00 Mil.

Exicure  (FRA:2H0) Long-Term Debt Explanation

Long-Term Debt is the sum of the carrying values as of the balance sheet date of all long-term debt, which is debt initially having maturities due after one year or beyond the operating cycle, if longer, but excluding the portions thereof scheduled to be repaid within one year or the normal operating cycle, if longer. Long-Term Debt includes notes payable, bonds payable, mortgage loans, convertible debt, subordinated debt and other types of long term debt.

Exicure Long-Term Debt Related Terms

Exicure Long-Term Debt Historical Data

* Premium members only.

The historical data trend for Exicure's Long-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Exicure Long-Term Debt Chart

Exicure Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Long-Term Debt
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Exicure Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Long-Term Debt Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
FRA:2H0
30GF Score
Exicure Inc FRA:2H0
Long-Term Debt is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Long-Term Debt →
What does a Long-Term Debt of €0.00 Mil mean?
Exicure (FRA:2H0) has a Long-Term Debt of €0.00 Mil as of Mar. 2026.
Is Exicure's Long-Term Debt too high?
Exicure's current Long-Term Debt is €0.00 Mil. Overall, Exicure has a GF Score™ of 30/100, reflecting its overall financial health beyond just this single metric.
How does Exicure's Long-Term Debt compare to TVRD and ANEB?
Exicure's Long-Term Debt of €0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Long-Term Debt for a Biotechnology company?
A good Long-Term Debt depends on the Biotechnology industry context. However, Long-Term Debt should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Long-Term Debt mean?
A high Long-Term Debt can signal that a stock is expensive relative to its fundamentals. Exicure's current Long-Term Debt is €0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Exicure stock overvalued right now?
Exicure (FRA:2H0) has a current Long-Term Debt of €0.00 Mil. The stock's GF Value™ is €0.36, compared to a current price of €1.16 — trading 222.2% above its estimated fair value. The current Long-Term Debt is €0.00 Mil. Exicure's overall GF Score™ is 30/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Long-Term Debt calculated?
Long-Term Debt is calculated from a company's financial statements. For Exicure (FRA:2H0), the current Long-Term Debt is €0.00 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Exicure (FRA:2H0) Overvalued in 2026?

Based on GuruFocus' analysis, Exicure stock appears to be overvalued. The current stock price of €1.16 is trading 222.2% above its estimated GF Value™ of €0.36.

Key valuation signals for FRA:2H0:

  • Long-Term Debt: €0.00 Mil
  • GF Value™: €0.36 vs. price of €1.16 (222.2% above fair value)
  • GF Score™: 30/100 with 2 warning signs

No single metric tells the full story. See the FRA:2H0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Exicure Business Description

Other Exchanges XCUR:USA2H0:Germany
Address 400 Seaport Court, Suite 102, Redwood City, CA, USA, 94063
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.
30GF Score

Get the complete analysis for FRA:2H0

Long-Term Debt is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.16
Price
€0.36
GF Value